Efficacy of Tianzhu Dingxuan Decoction as an Adjuvant Therapy in Patients with Posterior Circulation Ischemic Vertigo and its Impact on Vasomotor Factors and Neurotransmitters
Objective To study the clinical efficacy of Tianzhu Dingxuan decoction as an adjuvant therapy for pa-tients with posterior circulation ischemic vertigo and its impact on vasomotor factors and neurotransmitters.Methods From June 2019 to June 2022,120 patients with posterior circulation ischemic vertigo admitted to the People's Hospital of Henan University of Chinese Medicine were selected.They were divided into a control group and a study group using the random number table method,with 60 patients in each group.The control group received conventional Western medical treatment,while the study group received Tianzhu Dingxuan decoction in addition to the conventional treatment.After 2 weeks of treat-ment,the clinical efficacy and safety of the two groups were observed and compared,along with the changes in traditional Chinese medicine(TCM)syndrome scores,dizziness handicap inventory(DHI)scores,levels of vasomotor factors[calcitonin gene-related peptide(CGRP),and endothelin-1(ET-1)],and neurotransmitters[5-hydroxyindole acetic acid(5-HIAA),nerve growth factor(NGF),and γ-aminobutyric acid(GABA)]before and after treatment.Results After treatment,the total effective rate was significantly higher in the study group(91.67％,55/60)compared to the control group(76.67％,46/60),with a statistically significant difference(P＜0.05).Both groups showed significant reductions in TCM syndrome and DHI scores compared to before treatment,with a statistically significant difference(P＜0.05);the study group showed lower TCM syndrome and DHI scores than the control group,with a statistically significant difference(P＜0.05).Serum CGRP levels increased and ET-1 levels decreased significantly in both groups compared to before treatment,with a statis-tically significant difference(P＜0.05);the study group showed higher CGRP and lower ET-1 levels than the control group,with a statistically significant difference(P＜0.05).Serum levels of 5-HIAA,NGF,and GABA increased signifi-cantly in both groups compared to before treatment,with a statistically significant difference(P＜0.05);the study group showed higher 5-HI A A,NGF,and GABA levels than the control group,with a statistically significant difference(P＜0.05).The incidence of adverse reactions did not differ significantly between the two groups during the treatment period,without a statistically significant difference(P＞0.05).Conclusion Tianzhu Dingxuan decoction,as an adjuvant therapy,is effective in treating posterior circulation ischemic vertigo.It significantly alleviates vertigo symptoms,regulates levels of vasomotor factors and neurotransmitters,and is safe for use.
万方数据
维普
